DeepMed Research

Janssen Scientific Affairs, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Evaluate the Efficacy and Safety of (D/C/F/TAF) Once Daily Fixed Dose Combination (FDC) Regimen in Newly Diagnosed, Antiretroviral Treatment-naive Human Immunodeficiency Virus Type 1 (HIV-1) Infected Participants Receiving Care in a Test and Treat Model of Care

Phase 3

Completed

Conditions: HIV-1

Interventions: Drug: DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC

First Posted Date: 2017-07-24

Last Posted Date: 2025-02-04

Lead Sponsor: Janssen Scientific Affairs, LLC

Target Recruit Count: 109

Registration Number: NCT03227861

Locations: 🇺🇸
Spectrum Medical Group, Phoenix, Arizona, United States
🇺🇸
The Office of Franco Felizarta, MD, Bakersfield, California, United States
🇺🇸
Chatham County Health Department, Savannah, Georgia, United States

and more 12 locations

Multiple Myeloma Patient Registry

Terminated

Conditions: Multiple Myeloma

First Posted Date: 2017-06-08

Last Posted Date: 2025-02-03

Lead Sponsor: Janssen Scientific Affairs, LLC

Target Recruit Count: 85

Registration Number: NCT03180853

Locations: 🇺🇸
Arizona Oncology Associates, PC - HAL, Phoenix, Arizona, United States
🇺🇸
Mercy Research, Fort Smith, Arkansas, United States
🇺🇸
Genesis Cancer Center, Hot Springs, Arkansas, United States

and more 57 locations

A Study to Assess the Validation and Mapping of the Suicide Ideation and Behavior Assessment

Completed

Conditions: Suicidality

Interventions: Other: No Intervention

First Posted Date: 2017-03-21

Last Posted Date: 2025-02-03

Lead Sponsor: Janssen Scientific Affairs, LLC

Target Recruit Count: 130

Registration Number: NCT03085108

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
CNS Network, Garden Grove, California, United States
🇺🇸
Rutgers University, Piscataway, New Jersey, United States

and more 1 locations

Smartphones to Improve Rivaroxaban ADHEREnce in Atrial Fibrillation

Phase 4

Completed

Conditions: Atrial Fibrillation

Interventions: Other: No Intervention
Behavioral: Mobile Application Intervention

First Posted Date: 2016-12-19

Last Posted Date: 2018-10-26

Lead Sponsor: Janssen Scientific Affairs, LLC

Target Recruit Count: 139

Registration Number: NCT02996435

Study to Evaluate the Relative Bioavailability of Fixed-dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) as a Whole Tablet, as a Split Tablet, and as Crushed Tablet in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Darunavir (DRV)
Drug: Cobicistat (COBI)
Drug: Emtricitabine (FTC)
Drug: Tenofovir Alafenamide (TAF)

First Posted Date: 2016-12-07

Last Posted Date: 2025-02-03

Lead Sponsor: Janssen Scientific Affairs, LLC

Target Recruit Count: 30

Registration Number: NCT02984852

A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Daratumumab
Drug: Cyclophosphamide
Drug: Bortezomib
Drug: Dexamethasone

First Posted Date: 2016-11-01

Last Posted Date: 2021-10-08

Lead Sponsor: Janssen Scientific Affairs, LLC

Target Recruit Count: 101

Registration Number: NCT02951819

Comparative and Pragmatic Study of Golimumab Intravenous (IV) (Simponi Aria) Versus Infliximab (Remicade) in Rheumatoid Arthritis

Completed

Conditions: Arthritis, Rheumatoid

Interventions: Biological: Infliximab
Biological: Golimumab Intravenous (IV)
Biological: Biosimilar Infliximab

First Posted Date: 2016-04-05

Last Posted Date: 2020-04-15

Lead Sponsor: Janssen Scientific Affairs, LLC

Target Recruit Count: 1279

Registration Number: NCT02728934

Real-World Study of Enzalutamide and Abiraterone Acetate (With Prednisone) Tolerability

Completed

Conditions: Prostate Cancer

Interventions: Other: No Intervention

First Posted Date: 2016-01-26

Last Posted Date: 2025-02-03

Lead Sponsor: Janssen Scientific Affairs, LLC

Target Recruit Count: 108

Registration Number: NCT02663193

Family Intervention in Recent Onset Schizophrenia Treatment (FIRST)

Completed

Conditions: Schizophrenia

Interventions: Other: Caregiver psycho-education and skills training
Other: Caregiver support available at the study site
Drug: Paliperidone palmitate
Drug: Chlorpromazine
Drug: Droperidol
Drug: Fluphenazine
Drug: Haloperidol
Drug: Loxapine
Drug: Perphenazine
Drug: Pimozide
Drug: Prochlorperazine
Drug: Thiothixene
Drug: Thioridazine
Drug: Trifluoperazine
Drug: Aripiprazole
Drug: Asenapine
Drug: Clozapine
Drug: Iloperidone
Drug: Olanzapine
Drug: Paliperidone
Drug: Quetiapine
Drug: Risperidone
Drug: Ziprasidone

First Posted Date: 2015-11-09

Last Posted Date: 2019-01-23

Lead Sponsor: Janssen Scientific Affairs, LLC

Target Recruit Count: 296

Registration Number: NCT02600741

A Study of Rivaroxaban for Early Discharge of Low Risk Pulmonary Embolism From the Emergency Department

Phase 4

Completed

Conditions: Pulmonary Embolism

Interventions: Drug: Standard-of-care
Drug: Rivaroxaban

First Posted Date: 2015-10-22

Last Posted Date: 2018-06-01

Lead Sponsor: Janssen Scientific Affairs, LLC

Target Recruit Count: 114

Registration Number: NCT02584660

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy